mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
=== Canada === In Canada, one needs to put into writing what the child's circumstances are for being adopted. Some circumstances may include: the child's mental, physical, and emotional welfare, their background, religion, having a positive relationship, etc. If the child is an indigenous person, then the family must specify their plan to keep the child involved in their culture.
Stimulates parietal cell maturation and fundal growth. Causes chief cells to secrete pepsinogen, the zymogen (inactive) form of the digestive enzyme pepsin. Increases antral muscle mobility and promotes stomach contractions. Strengthens antral contractions against the pylorus, and relaxes the pyloric sphincter, which increases the rate of gastric emptying. Plays a role in the relaxation of the ileocecal valve. Induces pancreatic secretions and gallbladder emptying. May impact lower esophageal sphincter (LES) tone, causing it to contract, - although pentagastrin, rather than endogenous gastrin, may be the cause. Gastrin contributes to the gastrocolic reflex.
A crystal structure of the serotonin 5-HT2B receptor bound to LSD reveals an extracellular loop that forms a "lid" over the diethylamide end of the binding cavity and "traps" LSD in the binding pocket, which explains the slow rate of LSD unbinding from serotonin receptors. The related lysergamide lysergic acid amide (LSA) that lacks the diethylamide moiety is far less potent in comparison. Moreover, a specific residue in the binding pocket is partially responsible for the prolonged action of LSD, and this residue is found in the human protein but not in the receptors of rodents. LSD is an extraordinarily potent psychoactive drug and is among the most potent psychedelics known in humans. The very high potency of LSD in producing psychedelic-like effects is also the case in animals, including rodents and monkeys. It is unclear why LSD is so potent. The affinity and activational potency of LSD at the human serotonin 5-HT2A receptor in vitro is unremarkable compared to other psychedelics such as DOI and DOB. There is no evidence for its greater potency being related to pharmacokinetics or metabolism. It appears that the N,N-diethylamide moiety of LSD fits into a sterically constrained region of the serotonin 5-HT2A receptor that specifically accommodates this moiety. LSD, like other psychedelics, has been found to increase the expression of genes related to synaptic plasticity and hence to have psychoplastogenic effects. This appears to be mediated by serotonin 5-HT2A receptor agonism.
Sources: en.wikipedia.org
=== February === February 9, 2011 Latvia Latvia leaves deep recession with an annualised growth of 3.7% in the last quarter of 2010, meaning the Latvian economy only shrank by 0.2% in 2010, compared to 18% in 2009.
=== Improved diagnosis and treatment === The first attempt to establish a set of diagnostic criteria was also due to Charcot in 1868. He published what now is known as the "Charcot triad", consisting of nystagmus, intention tremor, and telegraphic speech (scanning speech). Charcot also observed cognition changes, describing his patients as having a "marked enfeeblement of the memory" and "conceptions that formed slowly". The diagnosis was based on Charcot triad and clinical observation until Schumacher made the first attempt to standardize criteria in 1965 by introducing some fundamental requirements: Dissemination of the lesions in time (DIT) and space (DIS), and that "signs and symptoms cannot be explained better by another disease process". The DIT and DIS requirement was later inherited by the Poser and McDonald criteria. During the 20th century, theories about the cause and pathogenesis were developed and effective treatments began to appear in the 1990s. Since the beginning of the 21st century, refinements of the concepts have taken place. The 2010 revision of the McDonald criteria allowed for the diagnosis of MS with only one proved lesion (CIS). In 1996, the US National Multiple Sclerosis Society (NMSS) (Advisory Committee on Clinical Trials) defined the first version of the clinical phenotypes that is in use. In this first version, they provided standardized definitions for four MS clinical courses: relapsing-remitting (RR), secondary progressive (SP), primary progressive (PP), and progressive relapsing (PR). In 2010, PR was dropped and CIS was incorporated.
=== Split and pool synthesis in solution === Han et al. described a method that made it possible to keep the advantages of both the high efficiency of S&P synthesis and that of a homogeneous media in the chemical reactions. In their method polyethyleneglycol (PEG) was used as soluble support in S&P synthesis of peptide libraries. MeO-CH2-CH2-O-(CH2-CH2-O)n-CH2-CH2-OH PEG proved suitable for this purpose since it is soluble in a wide variety of aqueous and organic solvents and its solubility provides homogeneous reaction conditions even when the attached molecule itself is insoluble in the reaction medium. Separation from the solution of the polymer and the synthesized compounds bound to it can be achieved by precipitation and filtration. The precipitation requires concentrating the reaction solutions then diluting with diethyl ether or tert-butyl methyl ether. Under carefully controlled precipitation conditions the polymer with the bound products precipitates in crystalline form and the unwanted reagents remain in solution. In the solid phase, S&P synthesis a single compound forms on each bead, and as a consequence, the number of compounds can't exceed the number of beads. So, the theoretical maximum number of compounds depends on the quantity of the solid support and the size of the beads. On 1 g polystyrene resin, for example, a maximum of 2 million compounds can be synthesized if the diameter of the resin beads is 90 μm, and 2 billion can be made if the bead size is 10 μm.
== Receptors involved in platelet adhesion to collagen == Membrane glycoproteins GPIa/IIa, GPVI and probably GPIV as well, function as collagen receptors, engaged in platelet adhesion to collagen. The leading role in the elimination of high-stress injury is taken by the glycoprotein Ib-IX-V complex.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.